Alpharma appoints new chief scientific officer

In this new role, Mr Warner will advise and guide multiple late-stage development projects, interface with regulatory agencies in the US and abroad, ensure technology platforms provide distinct and sustainable competitive advantages and make resource allocation decisions based upon increasingly complex choices.

Additionally, Mr Warner will support the newly created science and technology committee of the Alpharma board of directors. Mr Warner, who has been with Alpharma since 2002 and has served as the pharmaceuticals division president since 2005, will continue to serve on the company’s executive leadership team.

The company has also appointed Scott Shively as senior vice president of pharmaceutical commercial operations. He also will join the Alpharma executive leadership team. In addition to his existing sales and marketing responsibilities, Mr Shively will assume responsibility for the pharmaceutical supply chain, alliance management and the company’s operations in Ireland.

Dean Mitchell, president and CEO of Alpharma, said: “The restructuring of our pharmaceutical division will effectively align our organization with the expertise and focus necessary to address these issues and continue to create long-term shareholder value.”